-
Strong results for Keytruda in head and neck cancer
pharmatimes
October 25, 2018
MSD’s Keytruda improved overall survival by up to 39% in first-line head and neck cancer, new results show.
-
Daiichi Sankyo Announces Research Collaboration to Evaluate DS-8201, Keytruda
americanpharmaceuticalreview
September 21, 2018
Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of Merck to evaluate the combination of Daiichi Sankyo's investigational HER2 targeting antibody drug conjugate DS-8201 and Keytruda (pembrolizumab) in HER2 express
-
Merck follows Opdivo’s suit, prices Keytruda in China at half its U.S. tag
fiercepharma
September 20, 2018
When Bristol-Myers Squibb unveiled its price for Opdivo in China, industry watchers considered it a benchmark against which future immuno-oncology therapies will look to for their pricing strategies.
-
Merck extends I/O lead as EU Oks Keytruda in first line lung cancer
biopharmadive
September 17, 2018
Keytruda (pembrolizumab) continues to dominate in first-line NSCLC approvals, which have fueled its rapid sales growth and transformed Merck into an immunotherapy leader.
-
Priority review for MSD’s Keytruda for Merkel cell carcinoma
pharmatimes
September 14, 2018
US regulators are undertaking a priority review of MSD’s Keytruda for the treatment of adult and paediatric patients with recurrent locally advanced...
-
EC green-lights MSD’s Keytruda combo for lung cancer
September 13, 2018
The European Commission has approved MSD’s Keytruda for use in combination with Eli Lilly’s Alimta and platinum-based chemotherapy for the first-line treatment of some advanced lung cancers.
-
Keytruda scores ground-breaking European approval in lung cancer subgroup
September 13, 2018
Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based chemotherapy in the first-line...
-
MSD’s Keytruda Approved for Marketing in China in 164 Days, China to Speed Up to Enter the New Era of Immunotherapy
1°C
August 08, 2018
The State Drug Administration of China (SDA) updated the marketing application status of MSD’s Keytruda (pembrolizumab) on July 25, 2018 to “Approval completed-to be issued certificate”.
-
European backing for Merck's Keytruda rubs salt in Bristol-Myers' wounds
biospectrumasia
July 31, 2018
Merck’s Keytruda is one step closer to extending its dominance in the all-important previously untreated lung cancer market.
-
The day has come: Merck’s Keytruda surpasses Bristol-Myers Squibb’s Opdivo in Q2 sales
fiercepharma
July 30, 2018
Merck & Co.’s blockbuster cancer drug Keytruda has delivered again in the second quarter, and this time, it has seized the PD-1/L1 crown from Bristol-Myers Squibb’s archrival Opdivo.